Analyst Consensus ?
ConsensusHold33 ratings
Bullish1648.5%
Neutral1648.5%
Bearish13.0%
Becton, Dickinson and Company · BDX · FY2026 Q2 · Calendar Q2 2026
BDX Beats on EPS and Revenue, Raises Full-Year Guidance Amid Core Platform Strength
BD delivered a solid quarter powered by double-digit growth in its strategic platforms -- biologic drug delivery, Advanced Patient Monitoring, PureWick, and Advanced Tissue Regeneration -- which are outpacing the broader portfolio. The company raised full-year adjusted EPS guidance to $12.52-$12.72, reflecting management confidence in the New BD strategy. Headwinds in Alaris, vaccines, and China persist but are expected to diminish in FY27. Strong cash generation funded $2.3 billion in shareholder returns this quarter. An FDA warning letter at the El Paso facility introduces near-term regulatory risk, though no patient-safety signals have been identified. The stock jumped roughly 6% on the report, well ahead of the benchmark.
Reported Before market openNYSEHealthcare
$60.26B market cap
90quality score
Company context
Snapshot as of publicationOperating globally, Becton, Dickinson and Company (BD) is a prominent enterprise focused on the development, manufacturing, and distribution of a broad spectrum of medical technology. This includes essential medical supplies, sophisticated devices, advanced laboratory equipment, and critical diagnostic products. Its extensive customer base comprises healthcare providers, clinical institutions, medical researchers, pharmaceutical firms, and the general public around the world. The BD Medical division delivers a comprehensive suite of products primarily focused on medication management and drug delivery. This encompasses a variety of intravenous (IV) access solutions, such as peripheral and advanced catheters, central lines, acute dialysis catheters, and related vascular care items including needle-free connectors and closed-system drug transfer devices. It also provides essential injection equipment like hypodermic syringes, needles, anesthesia trays, enteral syringes, and sharps disposal systems.…
Earnings scorecard
Reported versus consensus
Reported EPS
$2.90
Consensus $3
EPS surprise
+4.3%
Reported versus consensus
Reported revenue
$4.71B
Consensus $4.67B
Revenue surprise
+0.9%
Reported versus consensus
Earnings History
Estimate
Beat
Miss
Match
Analyst 52W Price Targets
$168.4Current
$159Low
$197.9Average
$235.85High
Latest persisted target per named analyst; persisted current price from FN2's market snapshot as of Jul 29, 2026. Not an FN2 forecast.
Firm-level rating actions
FMP grade actions identify the grading firm, not a named analyst.
| Firm | Rating | Prior rating | Action | Date |
|---|---|---|---|---|
| Evercore ISI Group | Outperform | Outperform | Maintain | Jul 6, 2026 |
| Barclays | Overweight | Overweight | Maintain | May 11, 2026 |
| Wells Fargo | Equal Weight | Equal Weight | Maintain | May 8, 2026 |
| TD Cowen | Hold | Hold | Maintain | May 4, 2026 |
| Piper Sandler | Neutral | Neutral | Maintain | Apr 17, 2026 |
| Argus Research | Buy | Buy | Maintain | Mar 23, 2026 |
| Citigroup | Buy | Buy | Maintain | Feb 11, 2026 |
| RBC Capital | Sector Perform | Sector Perform | Maintain | Feb 10, 2026 |
| JP Morgan | Neutral | Neutral | Maintain | Feb 10, 2026 |
| Jefferies | Buy | Buy | Maintain | Feb 10, 2026 |
| Stifel | Buy | Buy | Maintain | Jan 7, 2026 |
| B of A Securities | Neutral | Neutral | Maintain | Jan 5, 2026 |
| Morgan Stanley | Overweight | Overweight | Maintain | Dec 2, 2025 |
| William Blair | Market Perform | Outperform | Downgrade | May 1, 2025 |
| Raymond James | Outperform | Outperform | Maintain | Aug 2, 2024 |
| Keybanc | Overweight | Sector Weight | Upgrade | Apr 12, 2023 |
| Goldman Sachs | Buy | Buy | Maintain | Nov 23, 2022 |
| SVB Leerink | Market Perform | Market Perform | Maintain | Feb 4, 2022 |
| UBS | Neutral | Neutral | Maintain | Aug 10, 2020 |
| CFRA | Hold | Hold | Maintain | May 8, 2020 |
| Cowen & Co. | Market Perform | Outperform | Downgrade | Feb 7, 2020 |
| Stifel Nicolaus | Buy | Buy | Maintain | Dec 16, 2019 |
| BMO Capital | Market Perform | Market Perform | Maintain | May 10, 2019 |
| Deutsche Bank | Buy | Buy | Maintain | Dec 7, 2018 |
| Bank of America | Neutral | Neutral | Maintain | Nov 5, 2014 |
| Canaccord Genuity | Hold | Hold | Maintain | Oct 7, 2014 |
| Argus | Buy | Buy | Maintain | Oct 7, 2014 |
| PiperJaffray | Overweight | Neutral | Upgrade | Sep 18, 2013 |
| ISI Group | Buy | Buy | Maintain | Jun 25, 2013 |
| Macquarie | Outperform | Neutral | Upgrade | May 10, 2013 |
| Mizuho | Neutral | Buy | Downgrade | Jan 22, 2013 |
| Leerink Swann | Market Perform | Outperform | Downgrade | Aug 3, 2012 |
| CLSA | Underperform | Outperform | Downgrade | Aug 3, 2012 |
Named analyst price targets
Upside is calculated against the persisted current price $168.4. FMP does not supply a rating on these named-analyst rows.
| Firm | Analyst | 52W target | Price when posted | Upside | Date |
|---|---|---|---|---|---|
| UBS | Analyst unavailable | $190 | $158.92 | +12.8% | Jul 28, 2026 |
| Evercore ISI | Analyst unavailable | $180 | $154.6 | +6.9% | Jul 6, 2026 |
| Barclays | Analyst unavailable | $204 | $149.43 | +21.1% | May 11, 2026 |
| Piper Sandler | Jason Bednar | $159 | $154.82 | -5.6% | Apr 17, 2026 |
| RBC Capital | Analyst unavailable | $175 | $155.43 | +3.9% | Apr 14, 2026 |
| Goldman Sachs | David Roman | $167 | $154.42 | -0.8% | Apr 10, 2026 |
| RBC Capital | Shagun Singh | $172 | $170.14 | +2.1% | Feb 10, 2026 |
| Barclays | Matt Miksic | $202 | $207.39 | +20.0% | Feb 10, 2026 |
| Piper Sandler | Analyst unavailable | $170 | $207.39 | +1.0% | Feb 10, 2026 |
| Piper Sandler | Jason Bednar | $161.16 | $159.91 | -4.3% | Jan 28, 2026 |
| Stifel Nicolaus | Analyst unavailable | $169.03 | $161.45 | +0.4% | Jan 7, 2026 |
| RBC Capital | Analyst unavailable | $165.09 | $154.39 | -2.0% | Dec 17, 2025 |
| Morgan Stanley | Patrick Wood | $165.09 | $150.8 | -2.0% | Dec 2, 2025 |
| Piper Sandler | Jason Bednar | $204.4 | $159.06 | +21.4% | Apr 23, 2025 |
| Evercore ISI | Vijay Kumar | $227.99 | $189.54 | +35.4% | Oct 1, 2024 |
| Citigroup | Joanna Wuensch | $216.19 | $190.2 | +28.4% | Oct 1, 2024 |
| Raymond James | Jayson Bedford | $212.26 | $187.96 | +26.0% | Aug 2, 2024 |
| Wells Fargo | Larry Biegelsen | $220.13 | $185.54 | +30.7% | Aug 2, 2024 |
| Evercore ISI | Becton Dickinson | $224.06 | $180.24 | +33.1% | Jul 2, 2024 |
| Goldman Sachs | David Roman | $215.41 | $176.94 | +27.9% | May 30, 2024 |
| Barclays | Matt Miksic | $245.28 | $184.5 | +45.7% | May 6, 2024 |
| Argus Research | David Toung | $235.85 | $190.83 | +40.1% | Apr 8, 2024 |
| Morgan Stanley | Analyst unavailable | $227.99 | $202.92 | +35.4% | Jan 6, 2023 |
| Citigroup | Analyst unavailable | $196.54 | $194.65 | +16.7% | Dec 12, 2022 |
| Goldman Sachs | Analyst unavailable | $213.84 | $185.9 | +27.0% | Nov 23, 2022 |
| Goldman Sachs | Analyst unavailable | $250.79 | $210.01 | +48.9% | Aug 16, 2022 |
| Stifel Nicolaus | Analyst unavailable | $220.13 | $187.4 | +30.7% | Jul 18, 2022 |
| Morgan Stanley | Analyst unavailable | $213.84 | $187.61 | +27.0% | Jul 15, 2022 |
| Citigroup | Analyst unavailable | $184.75 | $193.13 | +9.7% | Jul 11, 2022 |
| Wells Fargo | Larry Biegelsen | $231.92 | $197.26 | +37.7% | Jun 25, 2022 |
| Morgan Stanley | Analyst unavailable | $221.7 | $197.95 | +31.6% | May 6, 2022 |
| Piper Sandler | Analyst unavailable | $200.47 | $204.12 | +19.0% | May 6, 2022 |
| Bank of America Securities | Travis Steed | $227.99 | $209.27 | +35.4% | Mar 3, 2022 |
| Piper Sandler | Jason Bednar | $208.33 | $206.71 | +23.7% | Feb 3, 2022 |
Track every rating change on BDX the moment it posts. Free to start.
Start freeMarket reaction
prior-close to event-session close
Stock move
+5.9%
Event window
SPY move
-0.3%
Same window
Abnormal move
+6.2%
Stock minus SPY
Volume
2.1×
Versus trailing sessions
Subsequent drift
-1.4%
Up to 20 sessions
BDXSPY benchmark
Follow BDX with an agent that reads every filing, transcript, and price print. Free to start.
Try FN2 freeTranscript intelligence
What changed
Adjusted EPS of $2.90 beat the $2.78 consensus by 4.3%; revenue of $4.714B exceeded the $4.672B estimate by 0.9%. Full-year adjusted EPS guidance raised to $12.52-$12.72. Vitor Roque permanently appointed as CFO. Life Sciences separation completed at a 19x EBITDA multiple, now classified as discontinued operations. FDA warning letter received for El Paso facility producing ChloraPrep and PurPrep, resulting in a temporary ship hold. EnCompass Biopsy System launched in the U.S., entering the $450M global breast biopsy market. Manufacturing footprint reduced by roughly half to approximately 50 sites, driving an 8% productivity gain.
Guidance delta
Management raised full-year adjusted EPS guidance to $12.52-$12.72, up from prior expectations. Guidance sentiment on the call was characterized as raised, and management tone was confident. Revenue grew 2.6% year-over-year to $4.714B with an adjusted operating margin of 24.2%.
Key takeaways
- Adjusted EPS of $2.90 beat consensus of $2.78 by 4.3%, while revenue of $4.714B topped the $4.672B estimate by 0.9%.
- Double-digit growth in core platforms (biologics, APM, PureWick, tissue regeneration) is outpacing the broader portfolio.
- Headwinds persist in Alaris, vaccines, and China, but are expected to diminish in FY27.
- $2.3B returned to shareholders this quarter with $1.1B free cash flow generated year-to-date.
- Manufacturing footprint cut by roughly half to ~50 sites, driving an 8% productivity gain.
Management priorities
- Execute the $200M cost-out program with further manufacturing rationalization.
- U.S. launch of Revello Vascular Covered Stent planned for FY27.
- Expand HemoSphere Stream Module rollout in the U.S. and Europe.
- Scale PureWick at-home program and broader VA adoption.
- Introduce AI-enabled Pyxis Pro pharmacy automation platform.
Related earnings events
HealthcareSources
- Earnings call transcript and parsed analysis · 2026-05-11T10:29:34.698584+00:00
- FN2 earnings calendar · 2026-07-26T00:37:12.209961+00:00
- Polygon adjusted daily market bars · 2026-07-29T18:41:21.901164+00:00
- Financial Modeling Prep analyst price-target consensus and quote snapshot · 2026-07-29T18:41:21.898375+00:00
Methodology
Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.
Analyst target low, average, and high values are derived at request time from each named analyst's latest persisted FMP target. The current-price marker comes from FN2's persisted market snapshot. They are sell-side estimates, not an FN2 valuation or recommendation.
Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.
By FN2 Research · Updated . For educational purposes only; not investment advice.